Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 243

1.

Optimal Use of Adjuvant Bisphosphonates and Breast Cancer.

Powles TJ, Paterson AHG, Gralow JR.

J Clin Oncol. 2017 Aug 10;35(23):2719-2720. doi: 10.1200/JCO.2017.73.6157. Epub 2017 Jun 27. No abstract available.

PMID:
28654362
2.

Immunohistochemical Phenotype of Breast Cancer during 25-Year Follow-up of the Royal Marsden Tamoxifen Prevention Trial.

Detre SI, Ashley S, Mohammed K, Smith IE, Powles TJ, Dowsett M.

Cancer Prev Res (Phila). 2017 Mar;10(3):171-176. doi: 10.1158/1940-6207.CAPR-16-0247-T. Epub 2017 Jan 18.

3.

Impact of a Panel of 88 Single Nucleotide Polymorphisms on the Risk of Breast Cancer in High-Risk Women: Results From Two Randomized Tamoxifen Prevention Trials.

Cuzick J, Brentnall AR, Segal C, Byers H, Reuter C, Detre S, Lopez-Knowles E, Sestak I, Howell A, Powles TJ, Newman WG, Dowsett M.

J Clin Oncol. 2017 Mar;35(7):743-750. doi: 10.1200/JCO.2016.69.8944. Epub 2016 Dec 28.

4.

Relationship of ZNF423 and CTSO with breast cancer risk in two randomised tamoxifen prevention trials.

Brentnall AR, Cuzick J, Byers H, Segal C, Reuter C, Detre S, Sestak I, Howell A, Powles TJ, Newman WG, Dowsett M.

Breast Cancer Res Treat. 2016 Aug;158(3):591-6. doi: 10.1007/s10549-016-3885-x. Epub 2016 Jul 11.

5.

Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel.

Hadji P, Coleman RE, Wilson C, Powles TJ, Clézardin P, Aapro M, Costa L, Body JJ, Markopoulos C, Santini D, Diel I, Di Leo A, Cameron D, Dodwell D, Smith I, Gnant M, Gray R, Harbeck N, Thurlimann B, Untch M, Cortes J, Martin M, Albert US, Conte PF, Ejlertsen B, Bergh J, Kaufmann M, Holen I.

Ann Oncol. 2016 Mar;27(3):379-90. doi: 10.1093/annonc/mdv617. Epub 2015 Dec 17. Review.

PMID:
26681681
6.

Selective oestrogen receptor modulators (SERMs) for prevention of breast cancer.

Powles TJ.

Natl Med J India. 2013 Jul-Aug;26(4):194-6. No abstract available.

PMID:
24758440
7.

Extended adjuvant tamoxifen for breast cancer--a new era?

Powles TJ.

Lancet. 2013 Mar 9;381(9869):782-3. No abstract available.

PMID:
23219287
8.

Breast cancer incidence in postmenopausal women with osteoporosis or low bone mass using arzoxifene.

Powles TJ, Diem SJ, Fabian CJ, Neven P, Wickerham DL, Cox DA, Muram D, Agnusdei D, Dowsett SA, Amewou-Atisso M, Cummings SR.

Breast Cancer Res Treat. 2012 Jul;134(1):299-306. doi: 10.1007/s10549-012-2041-5. Epub 2012 Apr 8.

PMID:
22484799
9.

Prevention of breast cancer using SERMs.

Powles TJ.

Adv Exp Med Biol. 2008;630:232-6. Review.

PMID:
18637495
10.

Red clover isoflavones are safe and well tolerated in women with a family history of breast cancer.

Powles TJ, Howell A, Evans DG, McCloskey EV, Ashley S, Greenhalgh R, Affen J, Flook LA, Tidy A.

Menopause Int. 2008 Mar;14(1):6-12. doi: 10.1258/mi.2007.007033.

PMID:
18380954
11.

Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial.

Powles TJ, Ashley S, Tidy A, Smith IE, Dowsett M.

J Natl Cancer Inst. 2007 Feb 21;99(4):283-90.

PMID:
17312305
12.

Is raloxifene ready to be used for prevention of breast cancer?

Powles TJ.

Int J Fertil Womens Med. 2006 Sep-Oct;51(5):203-4. No abstract available.

PMID:
17269585
13.

Do we have a clinically useful breast cancer risk reduction agent for healthy women?

Powles TJ.

Nat Clin Pract Oncol. 2006 Dec;3(12):650-1. No abstract available.

PMID:
17139313
14.

Advances in treating metastatic bone cancer: summary statement for the First Cambridge Conference.

Lipton A, Berenson JR, Body JJ, Boyce BF, Bruland OS, Carducci MA, Cleeland CS, Clohisy DR, Coleman RE, Cook RJ, Guise TA, Pearse RN, Powles TJ, Rogers MJ, Roodman GD, Smith MR, Suva LJ, Vessella RL, Weilbaecher KN, King L.

Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6209s-6212s.

15.
16.

The effect of the stromal component of breast tumours on prediction of clinical outcome using gene expression microarray analysis.

Cleator SJ, Powles TJ, Dexter T, Fulford L, Mackay A, Smith IE, Valgeirsson H, Ashworth A, Dowsett M.

Breast Cancer Res. 2006;8(3):R32. Epub 2006 Jun 21.

17.

BRCA1/BRCA2 mutation status and analysis of cancer family history in participants of the Royal Marsden Hospital tamoxifen chemoprevention trial.

Kote-Jarai Z, Powles TJ, Mitchell G, Tidy A, Ashley S, Easton D, Assersohn L, Sodha N, Salter J, Gusterson B, Dowsett M, Eeles R.

Cancer Lett. 2007 Mar 18;247(2):259-65. Epub 2006 Jun 14.

PMID:
16777318
18.

Tamoxifen-induced anorexia is associated with fatty acid synthase inhibition in the ventromedial nucleus of the hypothalamus and accumulation of malonyl-CoA.

López M, Lelliott CJ, Tovar S, Kimber W, Gallego R, Virtue S, Blount M, Vázquez MJ, Finer N, Powles TJ, O'Rahilly S, Saha AK, Diéguez C, Vidal-Puig AJ.

Diabetes. 2006 May;55(5):1327-36.

19.

Good clinical response of breast cancers to neoadjuvant chemoendocrine therapy is associated with improved overall survival.

Cleator SJ, Makris A, Ashley SE, Lal R, Powles TJ.

Ann Oncol. 2005 Feb;16(2):267-72.

PMID:
15668282
20.

Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.

Martino S, Cauley JA, Barrett-Connor E, Powles TJ, Mershon J, Disch D, Secrest RJ, Cummings SR; CORE Investigators.

J Natl Cancer Inst. 2004 Dec 1;96(23):1751-61.

21.

American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.

Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J, Cobleigh MA, Mamounas EP, Goldstein LJ, Whelan TJ, Powles TJ, Bryant J, Perkins C, Perotti J, Braun S, Langer AS, Browman GP, Somerfield MR.

J Clin Oncol. 2005 Jan 20;23(3):619-29. Epub 2004 Nov 15. Review.

PMID:
15545664
22.

A cancer research (UK) randomized phase II study of idoxifene in patients with locally advanced/metastatic breast cancer resistant to tamoxifen.

Johnston SR, Gumbrell LA, Evans TR, Coleman RE, Smith IE, Twelves CJ, Soukop M, Rea DW, Earl HM, Howell A, Jones A, Canney P, Powles TJ, Haynes BP, Nutley B, Grimshaw R, Jarman M, Halbert GW, Brampton M, Haviland J, Dowsett M, Coombes RC; Cancer Research UK Phase I/II Committee.

Cancer Chemother Pharmacol. 2004 Apr;53(4):341-8. Epub 2004 Jan 13.

PMID:
14722733
23.

Studies of the potential utility of Ki67 as a predictive molecular marker of clinical response in primary breast cancer.

Assersohn L, Salter J, Powles TJ, A'hern R, Makris A, Gregory RK, Chang J, Dowsett M.

Breast Cancer Res Treat. 2003 Nov;82(2):113-23.

PMID:
14692655
24.

American Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant setting.

Winer EP, Hudis C, Burstein HJ, Bryant J, Chlebowski RT, Ingle JN, Edge SB, Mamounas EP, Gelber R, Gralow J, Goldstein LJ, Pritchard KI, Braun S, Cobleigh MA, Langer AS, Perotti J, Powles TJ, Whelan TJ, Browman GP.

J Clin Oncol. 2003 Jul 1;21(13):2597-9. Epub 2003 May 5. No abstract available.

PMID:
12732612
25.

Anti-oestrogenic chemoprevention of breast cancer-the need to progress.

Powles TJ.

Eur J Cancer. 2003 Mar;39(5):572-9. Review.

PMID:
12628835
26.

Anti-oestrogenic prevention of breast cancer--the make or break point.

Powles TJ.

Nat Rev Cancer. 2002 Oct;2(10):787-94. Review. Erratum in: Nat Rev Cancer 2002 Dec;2(12):964.

PMID:
12360281
27.

American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002.

Winer EP, Hudis C, Burstein HJ, Chlebowski RT, Ingle JN, Edge SB, Mamounas EP, Gralow J, Goldstein LJ, Pritchard KI, Braun S, Cobleigh MA, Langer AS, Perotti J, Powles TJ, Whelan TJ, Browman GP.

J Clin Oncol. 2002 Aug 1;20(15):3317-27. Review.

PMID:
12149306
28.

Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer.

Sotiriou C, Powles TJ, Dowsett M, Jazaeri AA, Feldman AL, Assersohn L, Gadisetti C, Libutti SK, Liu ET.

Breast Cancer Res. 2002;4(3):R3. Epub 2002 Mar 20.

29.

Results and implications of the Royal Marsden and other tamoxifen chemoprevention trials.

Ross PJ, Powles TJ.

Clin Breast Cancer. 2001 Apr;2(1):33-6; discussion 37-40. Review.

PMID:
11899380
30.

The feasibility of using fine needle aspiration from primary breast cancers for cDNA microarray analyses.

Assersohn L, Gangi L, Zhao Y, Dowsett M, Simon R, Powles TJ, Liu ET.

Clin Cancer Res. 2002 Mar;8(3):794-801.

31.

Breast cancer prevention.

Powles TJ.

Oncologist. 2002;7(1):60-4.

32.

The Royal Marsden Hospital (RMH) trial: key points and remaining questions.

Powles TJ.

Ann N Y Acad Sci. 2001 Dec;949:109-12.

PMID:
11795342
33.

Tamoxifen for the prevention of breast cancer: psychosocial impact on women participating in two randomized controlled trials.

Fallowfield L, Fleissig A, Edwards R, West A, Powles TJ, Howell A, Cuzick J.

J Clin Oncol. 2001 Apr 1;19(7):1885-92.

PMID:
11283119
34.

Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation.

Cauley JA, Norton L, Lippman ME, Eckert S, Krueger KA, Purdie DW, Farrerons J, Karasik A, Mellstrom D, Ng KW, Stepan JJ, Powles TJ, Morrow M, Costa A, Silfen SL, Walls EL, Schmitt H, Muchmore DB, Jordan VC, Ste-Marie LG.

Breast Cancer Res Treat. 2001 Jan;65(2):125-34. Erratum in: Breast Cancer Res Treat 2001 May;67(2):191.

PMID:
11261828
35.

Breast cancer prevention.

Powles TJ.

Breast Cancer Res. 2000;2(1):10-2. Epub 1999 Dec 17. Review. No abstract available.

36.

Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma.

Chang J, Ormerod M, Powles TJ, Allred DC, Ashley SE, Dowsett M.

Cancer. 2000 Dec 1;89(11):2145-52.

PMID:
11147583
37.

Re: Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study.

Powles TJ.

J Natl Cancer Inst. 2000 Dec 20;92(24):2040-2. No abstract available.

PMID:
11121468
38.

Chemoprevention options for BRCA1 and BRCA2 mutation carriers.

Eeles RA, Powles TJ.

J Clin Oncol. 2000 Nov 1;18(21 Suppl):93S-9S. Review.

PMID:
11060334
39.

Prognostic relevance of cerbB2 expression following neoadjuvant chemotherapy in patients in a randomised trial of neoadjuvant versus adjuvant chemoendocrine therapy.

Gregory RK, Powles TJ, Salter J, Chang JC, Ashley S, Dowsett M.

Breast Cancer Res Treat. 2000 Jan;59(2):171-5.

PMID:
10817352
40.

Tamoxifen for the prevention of breast cancer.

Fisher B, Powles TJ, Pritchard KJ.

Eur J Cancer. 2000 Jan;36(2):142-50. Review. No abstract available.

PMID:
10741272
41.

Clinical studies of apoptosis and proliferation in breast cancer.

Dowsett M, Archer C, Assersohn L, Gregory RK, Ellis PA, Salter J, Chang J, Mainwaring P, Boeddinghaus I, Johnston SR, Powles TJ, Smith IE.

Endocr Relat Cancer. 1999 Mar;6(1):25-8. Review.

42.

Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients.

Chang J, Powles TJ, Allred DC, Ashley SE, Makris A, Gregory RK, Osborne CK, Dowsett M.

Clin Cancer Res. 2000 Feb;6(2):616-21.

43.

Local relapse in primary breast cancer patients with unexcised positive surgical margins after lumpectomy, radiotherapy and chemoendocrine therapy.

Assersohn L, Powles TJ, Ashley S, Nash AG, Neal AJ, Sacks N, Chang J, Querci della Rovere U, Naziri N.

Ann Oncol. 1999 Dec;10(12):1451-5.

PMID:
10643535
44.

Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer.

Chang J, Powles TJ, Allred DC, Ashley SE, Clark GM, Makris A, Assersohn L, Gregory RK, Osborne CK, Dowsett M.

J Clin Oncol. 1999 Oct;17(10):3058-63.

PMID:
10506600
45.

The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation.

Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A, Jordan VC.

JAMA. 1999 Jun 16;281(23):2189-97. Erratum in: JAMA 1999 Dec 8;282(22):2124.

PMID:
10376571
46.

Reduction in angiogenesis after neoadjuvant chemoendocrine therapy in patients with operable breast carcinoma.

Makris A, Powles TJ, Kakolyris S, Dowsett M, Ashley SE, Harris AL.

Cancer. 1999 May 1;85(9):1996-2000.

PMID:
10223241
47.
48.

Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer: a pilot study.

Makris A, Powles TJ, Allred DC, Ashley SE, Trott PA, Ormerod MG, Titley JC, Dowsett M.

Breast Cancer Res Treat. 1999 Jan;53(1):51-9.

PMID:
10206072
49.

A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer.

Makris A, Powles TJ, Ashley SE, Chang J, Hickish T, Tidy VA, Nash AG, Ford HT.

Ann Oncol. 1998 Nov;9(11):1179-84.

PMID:
9862047
50.

Measurements of human breast cancer using magnetic resonance spectroscopy: a review of clinical measurements and a report of localized 31P measurements of response to treatment.

Leach MO, Verrill M, Glaholm J, Smith TA, Collins DJ, Payne GS, Sharp JC, Ronen SM, McCready VR, Powles TJ, Smith IE.

NMR Biomed. 1998 Nov;11(7):314-40. Review.

PMID:
9859939

Supplemental Content

Loading ...
Support Center